Apnimed IPO: revenue, profit and offering terms from its S-1
Apnimed priced its IPO at $16 a share on 31 Jul 2026 and raised $192 million. Its shares trade on Nasdaq as APMD. Revenue was $38.5 million in 2025, up 4.8 times from 2024, with a net loss of $128 million.
Headlines
- Revenue, 2025
- $38M
- Up 4.8 times on the year before
- Net loss, 2025
- $128M
- Revenue, First quarter of 2026
- $85M
- Up 27 times on a year earlier
- IPO price
- $16
- $192M raised
Apnimed IPO terms
From the final prospectus (424B4).
- Exchange
- Nasdaq Global Select Market
- Ticker
- APMD
- IPO price
- $16
- Shares offered
- 12,000,000
- Raised
- $192M
- Registered
- $184M, the amount the filing fee is paid on
- Underwriters
- BofA Securities, Evercore ISI, Cantor and LifeSci Capital
- First filed
- 10 Jul 2026
Apnimed revenue and profit
| Period | Revenue | Operating income | Net income |
|---|---|---|---|
| 2024 | $8M | - | -$111M |
| 2025 | $38M | -$54M | -$128M |
| First quarter of 2025 | $3M | - | - |
| First quarter of 2026 | $85M | $68M | $68M |
Apnimed share structure and company facts
- Employees
- 65
- Headquarters
- Cambridge, Massachusetts
Apnimed shares since the IPO
Latest close 26 Oct 2026
- IPO price
- $16
- Priced 31 Jul 2026
- First close
- $25.00
- +56% on the IPO price
- Latest close
- $18.95
- +18% on the IPO price
Apnimed's IPO filings
The registration statement, each amendment and the final prospectus, oldest first.
About the data
- Terms and financials are read from Apnimed's newest prospectus (424B4 filed 31 Jul 2026) by a Kadoa workflow. Check figures that matter against the filing.
- Registered is the amount the filing fee is paid on, often a placeholder before the price range is set.
- Raised is the IPO price times the shares sold, without the underwriters' option. Trading compares the first and latest close with the IPO price.